Toutes nos publications

Fabrication du plomb 212
  • Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003

  • 212Pb Alpha-Radioimmunotherapy targeting CD38 in Multiple Myeloma: a preclinical study

  • VCAM-1 targeted alpha-particle therapy for early brain metastases

  • Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy

  • Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model

  • 212Pb-NNV003 as a Novel Targeted Alpha Therapy for CD37 Positive B-cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

  • Safety and Outcome Measures of First-in-Human Intraperitoneal Alpha Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

  • Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

  • Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab

  • Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients

  • Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb

  • Biodistribution of 212Pb conjugated trastuzumab in mice

  • Significant systemic therapeutic effects of high-let immunoradiation by 212Pb-Trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice

En poursuivant votre navigation, vous acceptez l'utilisation des cookies. Pour plus d’informations, gérer ou modifier les paramètres des cookies sur votre ordinateur, lisez notre Politique Cookies dans nos mentions légales
J'accepte les cookies